146 related articles for article (PubMed ID: 6598184)
1. [Clinical usefulness of monoclonal antibody, CA 125 and CA 19-9 in ovarian cancer].
Saitoh S; Nakanishi A; Noda T; Ando Y; Katakami Y; Kiyozuka Y; Moriyama I; Ichijo M
Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2327-35. PubMed ID: 6598184
[No Abstract] [Full Text] [Related]
2. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
3. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
Rao GS; Hanjani P
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
[TBL] [Abstract][Full Text] [Related]
4. [The treatment of colonic and ovarian cancer with radioactive monoclonal antibodies against the CA l9-9 and CA 125 antigens].
Graef A; Romero MA; González M; Pierzo JA; Sosa R; Altamirano P
Gac Med Mex; 1992; 128(2):91-5. PubMed ID: 1302216
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
7. [A monoclonal antibody RIA as an antigenic determinant (CA 125) in ovarian cancer patients].
Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 1985 Sep; 20(5):257-60, 317. PubMed ID: 2417787
[No Abstract] [Full Text] [Related]
8. [Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)].
Kato T; Nishimura H; Hamai J; Yamabe T; Nakajima H; Nakano T; Noda K; Teshima K; Suzuki H; Ueda G
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2338-45. PubMed ID: 3007640
[No Abstract] [Full Text] [Related]
9. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the serum levels of a carbohydrate antigen 19-9 (CA 19-9) in patients with ovarian cancer].
Miyoshi T; Nishimura H; Ookura N; Morisaki H; Kobayashi H; Tasaki T; Ushijima H; Yakushiji M
Igaku Kenkyu; 1984 Dec; 54(8):796-800. PubMed ID: 6599577
[No Abstract] [Full Text] [Related]
11. A monoclonal antibody radioimmunoassay for an antigenic determinant CA125 in ovarian cancer patients.
Lian LJ; Hu XF; Liu WS; Wu AJ
Chin Med J (Engl); 1986 Sep; 99(9):721-6. PubMed ID: 2433106
[No Abstract] [Full Text] [Related]
12. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of CA 19-9 as a tumor marker for gynecologic malignancies].
Inoue M; Saitoh J; Abe Y; Inoue Y; Ueda G; Tanizawa O; Gamoh Y; Dan A; Satoh T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2411-4. PubMed ID: 3865972
[No Abstract] [Full Text] [Related]
14. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
15. CA-125: An evaluation.
Nuss R; Swor MG; Benrubi MD
J Fla Med Assoc; 1987 May; 74(5):329-32. PubMed ID: 2440975
[No Abstract] [Full Text] [Related]
16. [Possibilities and limitations of the clinical use of specific monoclonal antibodies for epithelial ovarian carcinomas: CA125K].
Pozzi V; D'Onofrio T; Cappa F; Mascaretti G; Meggiorini ML; Nusiner MP; Danese M
Minerva Ginecol; 1985 May; 37(5):253-7. PubMed ID: 3861960
[No Abstract] [Full Text] [Related]
17. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
Cruickshank DJ; Fullerton WT; Klopper A
Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
[TBL] [Abstract][Full Text] [Related]
19. Cross-specificity of the tumour marker CA 19-9: a case of ovarian carcinoma with recurrent venous thrombosis.
Smellie S; Lambert M
Acta Gastroenterol Belg; 1987; 50(2):241-2. PubMed ID: 3481507
[No Abstract] [Full Text] [Related]
20. Tumor marker in ovarian cancer. Tumor-associated antigen.
Barlow JJ; Bhattacharya M
N Y State J Med; 1977 Mar; 77(3):342-3. PubMed ID: 265013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
